A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. - Wikidata - wikimedia - TriplyDB

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

http://www.wikidata.org/entity/Q34619709

about

The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy Pharmacological management of IPF Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis New perspectives on management of idiopathic pulmonary fibrosis Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review Managing comorbidities in idiopathic pulmonary fibrosis Pulmonary hypertension: diagnostic and therapeutic challenges Acute and subacute idiopathic interstitial pneumonias The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review Right ventricular dysfunction in chronic lung disease Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges Update on diagnosis and treatment of idiopathic pulmonary fibrosis Update on therapeutic management of idiopathic pulmonary fibrosis Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis Predicting pulmonary fibrosis disease course from past trends in pulmonary function.Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.Fibrocytes and the pathogenesis of diffuse parenchymal lung disease.Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis.Pirfenidone treatment of idiopathic pulmonary fibrosis.Novel therapeutic approaches for pulmonary fibrosis.An official American Thoracic Society Statement: pulmonary hypertension phenotypes Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease Lung transplantation for pulmonary hypertension.Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias.Interstitial lung abnormalities and reduced exercise capacity.

P2860

Q21195756-FA57D998-535B-4C62-A5DD-D71503A15FAC Q26738458-780014E4-2E95-4DCA-A3EF-3EEB2998326C Q26748808-4DEE6AD7-6AD2-4175-AE7C-5CA70465C11C Q26750418-B7EDF1F8-4C8E-42FC-AC65-309CD1B34BDA Q26765586-4891446B-6C7B-4A8B-8A59-AFDA93098FBD Q26771309-24E910D0-6EC9-4B12-811F-83F07CD273CE Q26781255-6A3B15CA-590F-4F0D-88BB-2DDD674047AC Q26785617-8646166B-2F7C-461E-A415-8D771F6FD157 Q26796434-F2EC95A4-503B-48E4-83CD-3864AEDA6FE0 Q26824327-B6FB7672-2E50-4FEE-8B3B-55E27C0D0EFF Q26992007-2D79A3F8-734F-4B38-B8DF-FD2177F26749 Q27002670-9B32D369-ED14-49BD-A39D-5832304D5067 Q27021649-7A046EDD-196C-40B3-AA5F-A9E2A7F556B3 Q27499290-10DCFCD3-D297-4F22-A6C9-9B2F58E9E6E3 Q28083702-0E251A8A-555D-4E0F-89E3-2D61949BB9A8 Q28083944-A260D30A-6AFC-406C-92D2-D2E0CFF4FA23 Q28085094-F2DA17A5-1DEE-4008-9328-9BF30962A450 Q28308246-DA28E4E0-7961-45E5-8C1C-C061CF61F508 Q28484304-C0D2C72A-46EE-429E-836A-63F8AC2141E6 Q30359367-5ACACA50-A96B-4591-B5C0-83A1CA6785B2 Q30370058-B454D538-F95C-4A42-A667-E8A71BE6BB5D Q30407660-037A5F9F-85E8-4C08-8747-EEF76260BD10 Q30412203-9DFFC4B7-5240-438B-BDE8-3FAFDB9986AC Q30412726-59485806-55B5-4736-B17A-5C70ED93F496 Q30426516-45255534-F5D3-4681-8F28-5A7EC33D432F Q33738724-1EB3788B-AD97-4A44-982B-BB0734AE71F6 Q33908569-E7A78CAB-69AF-4BBA-ACB6-D19548C122D9 Q34432217-F5A2CAEB-10DF-4B95-8271-6BC6020C3B22 Q34480466-8F9FB433-067F-482D-9B3C-366E2238DCC3 Q34515601-589E2258-46B6-4AE4-9947-F80FE734819E Q34574174-18C0B751-363F-40E9-8484-38162C79C103 Q34903224-1BE73D09-4620-44D1-9BC6-7C7AC6CA0EF5 Q34919733-A3E3FC26-352F-4253-814C-3CB3123BB48B Q35121494-4FE85968-8BC9-4A18-B449-6EA99C3D3C0A Q35156618-627D0D61-9550-41BE-A390-BE70B19E78DD Q35164509-5EF0BAA1-78FB-425D-9AEA-D85FE44C31E6 Q35412426-077F851E-E4E2-42F7-B845-27502E3E8F53 Q35665777-4F26C00C-9F5A-4542-87AD-6B32B4A0C7BB Q35858996-60240258-A54D-4F4F-8382-61F892239B17 Q35889148-6C481BA6-D136-4F20-A0CC-5613AED8F4EF

P2860

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

http://www.wikidata.org/entity/Q34619709

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@ast

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@en

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@nl

type

label

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@ast

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@en

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@nl

prefLabel

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@ast

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@en

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@nl

P1433

Q34619709-F4D134FA-38C1-4373-BF6A-734A398F93F9

P1476

Q34619709-41203D3E-2357-45BF-A2DE-EAC1405EB37A

P2093

Q34619709-00826902-CA22-4D6E-92A1-933316A39D4D

Q34619709-0DBEC123-01BA-4CF1-84FA-E212E4CE887B

Q34619709-2126DB49-7FA7-4230-94DE-6493EFF77242

Q34619709-58BF5B96-F2FD-4953-8BEE-9D03AC546EBD

Q34619709-70E67C83-E925-4E17-92D2-56BB48E6BF25

Q34619709-C1D61231-071C-4402-9916-AACE815417DF

P2860

Q34619709-00830F47-3399-4794-8AEF-1F3A00A9985B

Q34619709-0756BF44-98E5-4930-B5CC-3CDEA38D8BED

Q34619709-0B8204BF-F481-4079-AAF9-58F5AEC83981

Q34619709-84893FAC-BD98-49C4-B650-8E25F6FB8213

Q34619709-97A13148-7724-439D-B23B-974146DD2754

Q34619709-BD3C180B-4085-4692-B46E-FEA5F8663E3C

Q34619709-F215445D-7EBD-4882-8B0A-3D0B992A1238

Q34619709-F437EAA9-F4E0-4510-A0A9-BD26B03E1D6B

Q34619709-F56A2F0F-4420-4135-B91D-0FDB261D3B84

P304

Q34619709-8D5EAA62-1158-4E67-9948-74533985E2D1

P31

Q34619709-9616B1EB-394D-47EA-A592-A1B0A16C5AC8

P356

Q34619709-A289E009-D7BE-4ECC-872D-00671F5B3E38

P407

Q34619709-B3115A70-076D-40DD-B96B-67E68ADF7DF7

P433

Q34619709-D3D18384-AE86-4D4C-A436-D0161058727F

P478

Q34619709-9D54C15B-E02F-42E1-824C-333051A61CE0

P50

Q34619709-05D2AAC3-CE1A-4E57-8B1E-698A00E6E030

P577

Q34619709-AEE8FFBF-8242-437D-BB15-F956AFDBC5FF

P5875

Q34619709-7EC44073-345B-4522-BC59-0616C5E0D68A

P698

Q34619709-90CF66EE-46B9-45BC-A90E-82D3A61B8D2A

P921

Q34619709-1B5A9412-0948-4B4F-BB2B-0ABF06CB8D09

P932

Q34619709-B8C56F8B-3FD3-4B67-BDAF-50E624D3DC80

P356

P1433

The New England Journal of Medicine

P1476

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

@en

P2093

David A Zisman

http://www.w3.org/2001/XMLSchema#string

Gary W Hunninghake

http://www.w3.org/2001/XMLSchema#string

Harold R Collard

http://www.w3.org/2001/XMLSchema#string

Idiopathic Pulmonary Fibrosis Clinical Research Network

http://www.w3.org/2001/XMLSchema#string

Kevin R Flaherty

http://www.w3.org/2001/XMLSchema#string

Marvin Schwarz

http://www.w3.org/2001/XMLSchema#string

P2860

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis

The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.

Classification of idiopathic interstitial pneumonias: making sense of the alphabet soup.

Sildenafil improves walk distance in idiopathic pulmonary fibrosis.

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.

Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale.

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.

Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire.

P304

620-628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1002110

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Kevin J Anstrom

P577

2010-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278194592

http://www.w3.org/2001/XMLSchema#string

P698

20484178

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

3587293

http://www.w3.org/2001/XMLSchema#string